J.P. Morgan Healthcare Conference
FDA Offers Orexigen Express Route to Contrave Resubmission
By Lynn Yoffee
Wednesday, January 9, 2013
If just 6 percent of diabetes patients who are obese take Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR), the company will reach $1 billion in sales in short order assuming the FDA grants approval. Given the agency's action this week, company execs have reason to feel confident.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.